细胞和基因供应链服务市场 - 全球产业规模、份额、趋势、机会和预测，按技术、应用、最终用户区域和竞争细分，2019-2029F

2023 年，全球细胞和基因供应链服务市场估值为13.2 亿美元，预计在预测期内将强劲增长，到2029 年复合年增长率为9.64%。活力的产业医疗保健产业正在迅速发展，以满足革命性细胞和基因疗法的需求。这些疗法引发了对专业供应链服务前所未有的需求，以满足其开发、製造和分销流程的独特需求。该市场的主要参与者包括物流公司、专业服务提供者、合约製造组织 (CMO) 和技术公司，这些公司提供针对处理先进疗法的复杂性而客製化的创新解决方案。慢性病盛行率上升、生物技术进步以及个人化医疗的采用等因素推动了市场的成长。此外，COVID-19 大流行凸显了弹性和高效供应链的必要性，进一步推动了细胞和基因治疗领域对强大解决方案的需求。

市场概况
预测期	2025-2029
2023 年市场规模	13.2亿美元
2029 年市场规模	22.8亿美元
2024-2029 年复合年增长率	9.64%
成长最快的细分市场	后勤
最大的市场	北美洲

此外，该行业还面临挑战，包括复杂的监管、冷链管理以及确保整个供应链中敏感生物材料的完整性和可追溯性。因此，公司正在基础设施、技术和策略合作伙伴关係方面进行大量投资，以优化供应链流程并降低风险。人们越来越重视永续性和道德考虑，利害关係人提倡环保解决方案和透明的供应链实践。展望未来，在生物技术不断进步、研发投资增加以及全球个人化医疗计画扩张的推动下，全球细胞和基因供应链服务市场将显着成长。儘管如此，持续创新和合作对于应对新出现的挑战和利用这个变革性行业的巨大机会至关重要。

主要市场驱动因素

细胞和基因疗法的进展

慢性病盛行率增加

生技投资不断增加

主要市场挑战

监理复杂性

冷链管理

可扩充性和容量限制

主要市场趋势

技术创新

不断增长的投资和伙伴关係

细分市场洞察

技术洞察

应用洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球细胞与基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按技术（存在于云端、存在于本地）
  • 按应用（订购和调度、样品收集、物流、后处理跟进）
  • 按最终使用者（生物库/细胞库、医院、研究机构、细胞治疗实验室、其他）
  • 按地区
  • 按公司划分 (2023)
• 市场地图
  • 依技术
  • 按应用
  • 按最终用户
  • 按地区

第 6 章：亚太地区细胞与基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲细胞与基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美细胞与基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 9 章：南美洲细胞与基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲细胞和基因供应链服务市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布（如果有）
• 併购（如有）

第 13 章：全球细胞与基因供应链服务市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• Biocair International Limited
• Arvato SE
• Associated Couriers, LLC.
• TrakCel Limited
• Parkoursc Inc.
• DHL
• McKesson Corporation
• Almac Group Limited
• Catalent Inc.
• Biostor Ltd.

第 16 章：策略建议

Global Cell and Gene Supply Chain Services Market was valued at USD 1.32 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 9.64% through 2029. The Global Cell and Gene Supply Chain Services Market represents a dynamic sector within the healthcare industry, rapidly evolving to meet the demands of revolutionary cell and gene therapies. These therapies have sparked unprecedented demand for specialized supply chain services that cater to the unique needs of their development, manufacturing, and distribution processes. Key players in this market include logistics firms, specialized service providers, contract manufacturing organizations (CMOs), and technology companies offering innovative solutions tailored to the complexities of handling advanced therapies. Factors such as the rising prevalence of chronic diseases, biotechnological advancements, and the uptake of personalized medicine drive the market's growth. Furthermore, the COVID-19 pandemic has underscored the necessity for resilient and efficient supply chains, further propelling demand for robust solutions in the cell and gene therapy domain.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.32 Billion
Market Size 2029	USD 2.28 Billion
CAGR 2024-2029	9.64%
Fastest Growing Segment	Logistics
Largest Market	North America

Also, the industry faces challenges, including regulatory intricacies, cold chain management, and ensuring the integrity and traceability of sensitive biological materials throughout the supply chain. Consequently, companies are making substantial investments in infrastructure, technology, and strategic partnerships to optimize supply chain processes and mitigate risks. There's a growing emphasis on sustainability and ethical considerations, with stakeholders advocating for environmentally friendly solutions and transparent supply chain practices. Looking ahead, the Global Cell and Gene Supply Chain Services Market is poised for significant growth, driven by ongoing biotechnological advancements, increased research and development investment, and the expansion of personalized medicine initiatives globally. Nevertheless, continuous innovation and collaboration will be critical to addressing emerging challenges and capitalizing on the vast opportunities in this transformative sector.

Key Market Drivers

Advancements in Cell and Gene Therapies

Advancements in cell and gene therapies are driving the growth of the global cell and gene supply chain services market. These therapies represent a groundbreaking approach to treating various diseases by targeting cellular and genetic causes. As research progresses and more therapies enter the market or clinical trials, the demand for specialized supply chain services rises. One key driver is the expanding portfolio of approved therapies and the growing pipeline of candidates in clinical development. This necessitates robust supply chain infrastructure to ensure timely and efficient delivery worldwide. Providers must navigate handling highly sensitive biological materials, strict temperature controls, and regulatory compliance.

Also, advancements in therapies require tailored logistics and distribution solutions. Many therapies have strict storage and transportation requirements, demanding specialized facilities and equipment. Providers invest in expertise and technology to meet these needs and ensure smooth delivery from manufacturing to clinical sites or patients' homes. As therapies become more prevalent, there's a focus on scaling up production. This requires scalable and flexible supply chain solutions to manage fluctuations in volume while ensuring quality and safety. Providers employ automation, robotics, and data analytics to optimize processes, manage inventory, and enhance visibility and transparency.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant driver fueling the growth of the global cell and gene supply chain services market. Chronic diseases, such as cancer, cardiovascular diseases, diabetes, and autoimmune disorders, pose a significant public health challenge worldwide, contributing to a substantial burden on healthcare systems and economies. As traditional treatment options often fall short in providing long-term solutions for these conditions, there is a growing demand for innovative therapies, including cell and gene therapies, that offer the potential for durable and personalized treatments.

The rise in chronic diseases is driving the development and adoption of cell and gene therapies as promising new treatment modalities. These advanced therapies target the underlying causes of diseases at the cellular and genetic levels, offering the potential to address unmet medical needs and provide more effective and targeted treatments for patients. With increasing recognition of the potential of cell and gene therapies to revolutionize healthcare, there is a growing pipeline of therapies in development targeting a wide range of chronic diseases.

As the demand for cell and gene therapies continues to grow, so does the need for specialized supply chain services to support their development, manufacturing, and distribution. The complexity and sensitivity of these therapies require stringent handling and storage conditions, as well as specialized logistics and transportation solutions to ensure their safe and efficient delivery to patients. Supply chain providers play a critical role in managing the logistics and distribution of these therapies, ensuring they reach patients in a timely and reliable manner while maintaining their potency and efficacy.

Moreover, the increasing prevalence of chronic diseases is driving investment and innovation in the biopharmaceutical industry, leading to advancements in manufacturing technologies and processes for cell and gene therapies. As manufacturing capacity expands to meet growing demand, supply chain providers must develop scalable and flexible solutions to support the efficient production and distribution of these therapies. This includes investing in state-of-the-art manufacturing facilities, automation technologies, and quality assurance systems to ensure product quality and compliance with regulatory requirements.

Growing Investment in Biotechnology

The growing investment in biotechnology is a key driver fueling the expansion of the global cell and gene supply chain services market. Biotechnology companies, pharmaceutical firms, and research institutions are increasingly channeling resources into the development of innovative therapies, particularly in the field of cell and gene therapy. This surge in investment is driven by several factors, including advances in scientific research, promising clinical trial results, and the potential for transformative treatments for a wide range of diseases.

Investment in biotechnology is driving the development and commercialization of a diverse array of cell and gene therapies targeting various medical conditions, such as cancer, genetic disorders, and autoimmune diseases. These therapies offer the potential for personalized and precise treatments that can address the underlying causes of diseases at the cellular and genetic levels. As a result, there is a growing pipeline of cell and gene therapies in various stages of development, ranging from early-stage research to late-stage clinical trials.

The increasing investment in biotechnology is also spurring growth in manufacturing capacity and infrastructure to support the production of cell and gene therapies at scale. Biopharmaceutical companies and contract manufacturing organizations (CMOs) are expanding their manufacturing facilities and investing in advanced technologies to meet the growing demand for these therapies. This expansion in manufacturing capacity creates opportunities for supply chain providers to offer specialized services to support the production, storage, and distribution of cell and gene therapies.

Furthermore, the growing investment in biotechnology is driving innovation in supply chain management and logistics to meet the unique requirements of cell and gene therapies. These therapies often have specific handling and storage requirements, such as cryogenic storage or strict temperature controls, to maintain their stability and efficacy. Supply chain providers are developing specialized solutions to meet these requirements, including temperature-controlled transportation, cold chain logistics, and quality assurance systems to ensure the integrity of these sensitive products throughout the supply chain.

Key Market Challenges

Regulatory Complexities

Regulatory complexities pose a significant challenge for stakeholders in the cell and gene supply chain services market. The development and commercialization of cell and gene therapies are subject to stringent regulations and oversight by regulatory agencies worldwide. Navigating these regulatory requirements can be challenging, particularly given the evolving nature of the field and the unique characteristics of these therapies. Ensuring compliance with regulations adds complexity to supply chain operations, requiring robust quality assurance systems, documentation, and processes to meet regulatory standards.

Cold Chain Management

Cold chain management presents a considerable challenge in the cell and gene supply chain services market. Many cell and gene therapies have strict temperature requirements to maintain their stability and efficacy. Ensuring the integrity of these therapies throughout the supply chain, from manufacturing to delivery to the patient, requires sophisticated cold chain logistics and storage solutions. Maintaining the required temperature conditions during transportation and storage poses logistical challenges, particularly for products with ultra-low temperature requirements or long-distance distribution networks.

Scalability and Capacity Constraints

Scalability and capacity constraints pose significant challenges in the cell and gene supply chain services market. As the demand for cell and gene therapies continues to grow, there is increasing pressure on manufacturing and distribution capacity to meet market needs. Scaling up production while maintaining product quality and compliance with regulatory requirements is a complex endeavor that requires substantial investment in infrastructure, technology, and expertise. Additionally, fluctuations in demand and production volumes can strain existing capacity and lead to bottlenecks in the supply chain.

Key Market Trends

Technological Innovations

One of the critical challenges in the cell and gene supply chain is maintaining the integrity and efficacy of these therapies, which often require precise temperature control. Technological innovations in temperature-controlled logistics solutions are addressing this challenge by providing advanced monitoring and control systems to ensure that therapies remain within the required temperature range throughout the supply chain. These solutions leverage sensors, data analytics, and real-time monitoring to detect and mitigate temperature excursions, thereby safeguarding product quality and patient safety.

Blockchain technology is revolutionizing supply chain management by providing a transparent and immutable record of product movement and transactions. In the cell and gene supply chain services market, blockchain-based traceability platforms are enhancing transparency, security, and traceability across the entire value chain. These platforms enable stakeholders to track the journey of therapies from manufacturing facilities to patients, ensuring compliance with regulatory requirements and minimizing the risk of counterfeiting or fraud. By providing a decentralized and tamper-proof record of transactions, blockchain technology enhances trust and accountability in the supply chain ecosystem.

Automation and robotics are driving efficiency and scalability in the cell and gene supply chain services market. Automated systems streamline manufacturing processes, reduce human error, and increase throughput, enabling companies to scale up production to meet growing demand. Robotics technology is also being utilized in warehouse management and logistics operations to improve inventory management, order fulfillment, and transportation. By automating repetitive tasks and optimizing workflows, automation and robotics technologies enhance productivity and reduce costs throughout the supply chain.

Data analytics and artificial intelligence (AI) are revolutionizing decision-making in the cell and gene supply chain services market. Advanced analytics tools enable stakeholders to analyze vast amounts of data generated throughout the supply chain, identify trends, and optimize operations in real time. AI-powered algorithms can predict demand, optimize inventory levels, and improve route planning for transportation, thereby enhancing efficiency and reducing costs. By leveraging data analytics and AI, supply chain providers can gain valuable insights into their operations, improve decision-making, and drive continuous improvement across the entire supply chain.

Growing Investment and Partnerships

The global cell and gene supply chain services market is experiencing a significant boost due to growing investment and strategic partnerships among stakeholders. As cell and gene therapies emerge as promising treatment modalities for various diseases, companies across the biopharmaceutical and logistics sectors are increasing their investments and forming partnerships to address the unique challenges associated with the supply chain for these advanced therapies. One of the key drivers of the growth in investment is the expanding pipeline of cell and gene therapies in development. Pharmaceutical companies, biotech startups, and academic institutions are investing heavily in research and development to advance these therapies through clinical trials and regulatory approval processes. As the number of therapies in the pipeline increases, so does the demand for specialized supply chain services to support their manufacturing, storage, and distribution.

In addition to direct investment in research and development, companies are also investing in infrastructure and technology to enhance the efficiency and reliability of the supply chain for cell and gene therapies. This includes investments in manufacturing facilities, cold chain logistics, and quality assurance systems to ensure the safe and timely delivery of therapies to patients worldwide. By investing in infrastructure and technology, companies can improve the scalability, flexibility, and resilience of the supply chain, thereby accelerating the commercialization and adoption of cell and gene therapies.

Strategic partnerships are also playing a crucial role in driving growth in the cell and gene supply chain services market. Companies are forming partnerships with other stakeholders, including logistics providers, technology firms, and regulatory agencies, to collaborate on developing innovative solutions to address the unique challenges of the supply chain for cell and gene therapies. These partnerships enable companies to leverage each other's expertise, resources, and networks to overcome barriers and drive progress in the field.

Furthermore, partnerships between biopharmaceutical companies and contract manufacturing organizations (CMOs) are becoming increasingly common as companies seek to scale up production and meet growing demand for cell and gene therapies. By partnering with CMOs, companies can access specialized manufacturing capabilities and expertise, allowing them to bring therapies to market more quickly and efficiently.

Segmental Insights

Technology Insights

Based on the technology, presence on cloud segment emerged as the dominant segment in the global cell and gene supply chain services market in 2023. This can be attributed to several factors including its scalability, real-time visibility, collaboration capabilities, and accessibility, which collectively drive efficiency, innovation, and growth in the cell and gene therapy supply chain ecosystem.

Application Insights

Based on the application, logistics segment emerged as the dominant segment in the global cell and gene supply chain services market in 2023. The dominance of the logistics segment in the Global Cell and Gene Supply Chain Services market in 2023 underscores its critical role in ensuring the efficient and reliable delivery of cell and gene therapies. Advanced logistics solutions enable providers to navigate regulatory complexities, optimize supply chain efficiency, and ensure the safe transportation of therapies, ultimately driving growth and innovation in the cell and gene therapy ecosystem

Regional Insights

North America emerged as the dominant player in the global cell and gene supply chain services market in 2023, holding the largest market share. North America boasts advanced infrastructure and logistics capabilities, making it well-equipped to support the complex supply chain requirements of cell and gene therapies. The region has a dense network of manufacturing facilities, distribution centers, and transportation networks, facilitating the efficient and timely delivery of therapies to patients across the continent and beyond. Furthermore, North America leads the world in biotechnology innovation and investment, with a thriving ecosystem of biopharmaceutical companies, research institutions, and academic centers.

Key Market Players

Biocair International Limited

Arvato SE

Associated Couriers, LLC.

TrakCel Limited

Parkoursc Inc.

DHL

McKesson Corporation

Almac Group Limited

Catalent Inc.

Biostor Ltd.

Report Scope:

In this report, the Global Cell and Gene Supply Chain Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Cell and Gene Supply Chain Services Market, By Technology:

Presence on cloud Presence on-premises

Global Cell and Gene Supply Chain Services Market, By Applications:

Ordering and scheduling Sample collection Logistics Post treatment follow-up

Global Cell and Gene Supply Chain Services Market, By End-User:

Biobank/ cell-bank Hospitals Research institutes Cell therapy labs Others

Global Cell and Gene Supply Chain Services Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Supply Chain Services Market.

Available Customizations:

Global Cell and Gene Supply Chain Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Cell and Gene Supply Chain Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Presence on cloud, Presence on-premises)
  • 5.2.2. By Applications (Ordering and scheduling, Sample collection, Logistics, Post treatment follow-up)
  • 5.2.3. By End User (Biobank/ cell-bank, Hospitals, Research institutes, Cell therapy labs, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Technology
  • 5.3.2. By Applications
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Cell and Gene Supply Chain Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Applications
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cell and Gene Supply Chain Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Applications
      • 6.3.1.2.3. By End User
  • 6.3.2. India Cell and Gene Supply Chain Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Applications
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Cell and Gene Supply Chain Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Applications
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Cell and Gene Supply Chain Services Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Applications
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Cell and Gene Supply Chain Services Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Applications
      • 6.3.5.2.3. By End User

7. Europe Cell and Gene Supply Chain Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Applications
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cell and Gene Supply Chain Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Applications
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Cell and Gene Supply Chain Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Applications
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Cell and Gene Supply Chain Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Applications
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cell and Gene Supply Chain Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Applications
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Cell and Gene Supply Chain Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Applications
      • 7.3.5.2.3. By End User

8. North America Cell and Gene Supply Chain Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Applications
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cell and Gene Supply Chain Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Applications
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Cell and Gene Supply Chain Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Applications
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Cell and Gene Supply Chain Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Applications
      • 8.3.3.2.3. By End User

9. South America Cell and Gene Supply Chain Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Applications
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cell and Gene Supply Chain Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Applications
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Cell and Gene Supply Chain Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Applications
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Cell and Gene Supply Chain Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Applications
      • 9.3.3.2.3. By End User

10. Middle East and Africa Cell and Gene Supply Chain Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Applications
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cell and Gene Supply Chain Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Applications
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Cell and Gene Supply Chain Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Applications
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Cell and Gene Supply Chain Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Applications
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Cell and Gene Supply Chain Services Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Technology
      • 10.3.4.2.2. By Applications
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches ( If Any)
• 12.3. Mergers & Acquisitions ( If Any)

13. Global Cell and Gene Supply Chain Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Biocair International Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Arvato SE
• 15.3. Associated Couriers, LLC.
• 15.4. TrakCel Limited
• 15.5. Parkoursc Inc.
• 15.6. DHL
• 15.7. McKesson Corporation
• 15.8. Almac Group Limited
• 15.9. Catalent Inc.
• 15.10. Biostor Ltd.

16. Strategic Recommendations